Your browser is no longer supported. Please, upgrade your browser.
PFE Pfizer Inc. daily Stock Chart
Pfizer Inc.
IndexDJIA S&P500 P/E30.11 EPS (ttm)1.22 Insider Own0.10% Shs Outstand6.15B Perf Week-0.08%
Market Cap225.95B Forward P/E13.97 EPS next Y2.63 Insider Trans-13.45% Shs Float6.06B Perf Month6.59%
Income7.59B PEG4.25 EPS next Q0.62 Inst Own76.40% Short Float0.84% Perf Quarter11.42%
Sales50.99B P/S4.43 EPS this Y-21.50% Inst Trans-0.22% Short Ratio1.99 Perf Half Y21.92%
Book/sh10.25 P/B3.58 EPS next Y7.35% ROA- Target Price38.98 Perf Year9.37%
Cash/sh3.16 P/C11.62 EPS next 5Y7.09% ROE- 52W Range27.71 - 37.19 Perf YTD15.99%
Dividend1.20 P/FCF- EPS past 5Y1.60% ROI8.00% 52W High-1.59% Beta0.83
Dividend %3.27% Quick Ratio1.20 Sales past 5Y-5.60% Gross Margin79.20% 52W Low32.07% ATR0.43
Employees97900 Current Ratio1.40 Sales Q/Q19.70% Oper. Margin- RSI (14)66.34 Volatility0.80% 1.21%
OptionableYes Debt/Eq0.62 EPS Q/Q28.90% Profit Margin- Rel Volume0.49 Prev Close36.74
ShortableYes LT Debt/Eq0.44 EarningsAug 02 BMO Payout- Avg Volume25.51M Price36.60
Recom2.20 SMA202.04% SMA504.69% SMA20013.46% Volume872,175 Change-0.38%
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Apr-15-13Reiterated Barclays Equal Weight $25 → $32
Jan-30-13Reiterated UBS Buy $29 → $31
Jan-30-13Reiterated Argus Buy $28 → $32
Jul-25-16 08:30AM  Spark Therapeutics and Pfizer Announce Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity GlobeNewswire
05:47AM  The Economy, Interest Rates, Earnings and the Markets
Jul-24-16 11:40AM  3 Important Takeaways From Johnson & Johnson's Second-Quarter Earnings at Motley Fool
Jul-22-16 01:14PM  How Did Johnson & Johnsons Segments Perform in 2Q16?
12:13PM  Six Major Biotech Acquisitions You Could See in 2016 (Part 2) at Forbes
08:26AM  Can You Guess Which Pharma Giant Spends $1 Billion-Plus a Year On Direct-To-Consumer Ads? at Motley Fool
08:06AM  Will Pfizer Book Another Healthy Quarter?
12:01AM  Facing Cancer Drug Shortage, U.S. Relies on Banned Chinese Plant at Bloomberg
Jul-21-16 04:41PM  How Analysts Think Investors Should Play Vertex Pharmaceuticals
01:49PM  How Did Novartiss 2Q16 Earnings Stand up to Analyst Estimates?
12:00PM  Is biotech back?
11:54AM  Fresenius Bid for Pfizers Pumps Unit Said to Stall on Valuation at Bloomberg
09:03AM  These 5 Healthcare Stocks Have Huge Dividend Yields -- Are Any Worth Buying? at Motley Fool
08:40AM  Opioid Addiction: What To Do When A Loved One Is Hooked, According To Science
07:30AM  Spark Therapeutics and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B GlobeNewswire
Jul-20-16 04:25PM  Dollars and Sense: The Companies that Should be on Your Watch List at CNBC
03:32PM  Beech Hill Advisors Top Stock Picks for Q3; Apple Inc. (AAPL) Leads the Pack at Insider Monkey
01:30PM  2 Growth & Income Titans to Buy Today
12:48PM  Dollars & Sense: Jim Lebenthal's Watchlist
11:43AM  The good and bad of investing for a President Trump at CNBC
11:17AM  U.S. healthcare stock bulls look past political risks
Jul-19-16 12:00PM  Why a Trump Win Could Be Good News for Pfizer, IBM at
09:34AM  J&J (JNJ) Stock Gains on Q2 Earnings and Improved Outlook
08:22AM  5 Big Pharma Stocks Struggling to Raise Their Dividends at Motley Fool
08:00AM  Pfizer Receives World Health Organization Prequalification for Multi-Dose Vial Presentation of Prevenar 13® Business Wire
Jul-18-16 06:42PM  Roche's Gazyva Fails in Phase III B-cell Lymphoma Study
11:51AM  Dow 30 Stock Roundup: JPM Q2 Impresses, Orders for Boeing & United Technologies
08:30AM  Pharmaceutical Studies & Trials of Individual Cannabinoids Aim to Develop Cannabis Strains That Specifically Target Cancer Pain and Nausea CNW Group
06:15AM  ARIA Study Shows Superior Efficacy of Triumeq® for Treatment-naïve Women Living with HIV PR Newswire
Jul-17-16 05:54AM  Herd Mentality
Jul-16-16 09:15AM  Pharmaceutical Stocks May Be the Best Total Return Play: 3 to Buy Now at 24/7 Wall St.
08:09AM  Saturday links: zero-martini lunches
Jul-15-16 08:02PM  How Much Upward Potential Does Roche Really Have?
03:13PM  Pfizer's Split: A Double-Edged Sword? at Forbes
01:01PM  Yum!, Pepsi Among 10 NYSE Stocks Hitting 52-Week Highs Thursday at Insider Monkey
09:51AM  Ultragenyx (RARE) Reports Positive Phase III rhGUS Data
Jul-14-16 06:42PM  US Market Indexes Achieve New Highs
06:20PM  Investing in Big Pharma: Pointers on Pfizer
04:58PM  Business interests hit U.S. Treasury curb on overseas tax deals Reuters
04:42PM  Drug Companies Really Dont Care About the Price Hike Backlash at Fortune
04:01PM  Goldman Sachs, Apple Boost DJIA on Thursday at 24/7 Wall St.
01:19PM  Stocks Up Broadly Again; Will Dow Industrials Beat Nasdaq This Year?
12:10PM  Pfizer Publishes Final Data from Atopic Dermatitis Studies
08:58AM  Pfizer's Russia Deal Shows Country Still Open To Western Business at Forbes
08:40AM  5 Companies Likely Buying Back the Most Stock in June and July at 24/7 Wall St.
Jul-13-16 03:51PM  Why Did Jazz Fall after Celator Acquisition Announcement?
03:22PM  Merck to Axe Jobs As Part of New Research Focus at Fortune
02:04PM  GE Dives Deeper Into Cell Therapy As Juno, Kite Take Off
11:04AM  How Will Recent Developments Affect Allergan?
10:50AM  Corporate inversions help make 2015 record year for foreign investment in U.S. at MarketWatch
09:25AM  Pfizer (PFE) Gets FDA Nod for Label Expansion of Prevnar 13
09:15AM  Short Sellers Run for Cover From Major Pharma at 24/7 Wall St.
08:23AM  Theresa May to be Appointed New U.K. Prime Minister
08:00AM  Pfizer Announces the Publication of Final Results from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment in Patients with Mild to Moderate Atopic Dermatitis Business Wire
Jul-12-16 08:28PM  Sucampo to Stop Developing Cobiprostone for Oral Mucositis
08:20PM  Shire's (SHPG) Dry Eye Disease Drug Xiidra Gets FDA Nod
05:49PM  FDA Panel Resoundingly Backs Amgen's Biosimilar Humira
05:39PM  Lower-cost biotech drug gets thumbs up from FDA panel
04:52PM  FDA expands use of Pfizer's best-selling pneumonia vaccine Reuters
04:48PM  Will Pfizer (PFE) Stock Be Affected by Pneumonia Vaccine Approval?
04:25PM  FDA approves Pfizer's pneumonia vaccine for younger adults at MarketWatch
04:04PM  Pfizer Receives FDA Approval for Prevnar 13® in Adults Age 18 Through 49 Business Wire
Jul-11-16 05:09PM  Facebook, General Electric Top S&P 500's Five Biggest Stocks In Buy Range
01:50PM  Top 7 Research Reports for July 11, 2016
01:06PM  JNJ VS. PFE: Which Is The Better Large Cap Pharma Stock?
09:23AM  Pfizer Reports Positive Data on Kidney Cancer Drug Sutent
09:02AM  May Says U.K. Must Defend Its Drugmakers From Overseas Takeovers at Bloomberg
01:05AM  A Look at Alexions 2016 Guidance
Jul-10-16 04:07PM  Sentiment Turns On A Dime
07:21AM  Here's How Pfizer's Protecting Its Kidney Cancer Drug From New Competitors at Motley Fool
Jul-09-16 10:39AM  These 4 Stocks Can Save You From The Next Market Crash at Forbes
09:25AM  Viagra Price Drops 50% as Drug Faces Competition at 24/7 Wall St.
08:11AM  3 Top Dividend Stocks for Retirees to Buy at Motley Fool
Jul-08-16 06:46PM  [$$] Bill Ackman's Pershing Square Sells Off Another 6 Million Shares in Zoetis at The Wall Street Journal
04:10PM  Icagen, out from under Pfizer's umbrella, raises $1.5 million at
12:05PM  Pfizers Recent Corporate and Pipeline Developments
12:05PM  What Are Pfizers Major Product Developments?
11:34AM  Alnylam (ALNY) Begins Phase I/II Study on Chronic HBV Drug
10:34AM  Pfizer's Phase 3 S-TRAC Trial Of SUTENT Meets Primary Endpoint
09:32AM  Amgen's Biosimilar Humira Gets FDA Support Ahead Of Panel
08:00AM  Pfizer Announces Positive Top-Line Results From Phase 3 S-TRAC Trial of SUTENT® (sunitinib) as Adjuvant Therapy in Patients at High Risk of Recurrent Renal Cell Carcinoma Business Wire
Jul-07-16 05:02PM  Spike in drug prices comes from sector without competition at MarketWatch
04:54PM  Merck KGaA/Pfizer Avelumab in JAVELIN Ovarian 100 Study
04:40PM  Surprise: JNJ Just Did Celgene a Huge Favor
01:25PM  Pfizer Inc. : PFE-US: Dividend Analysis : August 05th, 2016 (record date) : By the numbers : July 7, 2016
11:21AM  Medivation: Why Would They Even Consider Selling? at
10:02AM  Bristol-Myers Buys Cormorant, Focus on Immuno-Oncology
Jul-06-16 08:06PM  What Can We Expect from the Pfizer-Anacor Deal?
08:06PM  The Pfizer-Anacor Deal Wrapped Up in June: Now What?
07:01PM  Pfizer Drug Wins U.K. Support Following Overhaul of Cancer Fund at Bloomberg
06:15PM  Cramer: My biggest mistakes made investing
04:37PM  Pfizer, Germany's Merck begin large ovarian cancer trial
03:00PM  How the Obama Administration Is Escalating the War on Opioids at Fortune
02:48PM  Pfizer agrees to note addiction risks in opioid marketing
02:11PM  Pfizer agrees to Chicago's request to disclose narcotic painkiller risk at CNBC
01:51PM  [$$] Medivation confident drugs pipeline will win over suitors at Financial Times
12:07PM  Analyst Estimates for Pfizer: Why Should We Take Notice?
11:35AM  [$$] Top U.S. Pharma Themes for the Second Half at
11:22AM  6 High-Yield Dividend Stocks With Promising Charts
09:20AM  [$$] Pfizer Offers $20 Million for Bind Therapeutics Assets at The Wall Street Journal
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; and collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., and Merck KGaA. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAMELIO FRANK AExecutive Vice PresidentMay 26Option Exercise24.43100,0002,443,000472,994May 27 11:03 AM
DAMELIO FRANK AExecutive Vice PresidentMay 26Sale34.49100,0003,449,115372,994May 27 11:03 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Option Exercise25.8786,0002,224,820271,663May 26 10:07 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Sale33.9786,0002,921,147185,663May 26 10:07 AM
YOUNG JOHN DGroup PresidentMay 10Option Exercise25.8741,7001,078,779200,399May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Option Exercise24.43192,0004,690,560564,994May 11 06:04 PM
YOUNG JOHN DGroup PresidentMay 10Sale33.5341,7001,398,277158,699May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Sale33.66192,0006,462,579372,994May 11 06:04 PM
READ IAN CChairman & CEOMay 09Option Exercise25.74275,0007,078,2501,471,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Option Exercise22.2823,884532,136199,735May 11 04:35 PM
HILL CHARLES HExecutive Vice PresidentMay 09Sale33.8429,6001,001,65160,828May 11 04:35 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Sale33.7167,8842,288,669131,851May 11 04:35 PM
READ IAN CChairman & CEOMay 09Sale33.80275,0009,295,0391,196,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 05Option Exercise22.2856,0161,248,036231,867May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 05Sale33.7156,0161,888,144175,851May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Option Exercise22.2820,100447,828195,951May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Sale33.8720,100680,762175,851May 06 09:51 AM
DAMELIO FRANK AExecutive Vice PresidentMay 03Sale33.6587,0792,930,208372,994May 05 05:27 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541274,756Feb 26 03:05 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 24Option Exercise18.9062,4531,180,362140,772Feb 26 03:05 PM
OLSON LAURIE JExecutive Vice PresidentFeb 24Option Exercise18.9018,984358,79889,467Feb 26 03:05 PM
READ IAN CChairman & CEOFeb 24Option Exercise18.90584,11211,039,7172,030,151Feb 26 03:05 PM
SUSMAN SALLYExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541263,151Feb 26 03:05 PM
YOUNG JOHN DGroup PresidentFeb 24Option Exercise18.9052,570993,573188,679Feb 26 03:05 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 24Option Exercise18.9034,171645,832210,943Feb 26 03:05 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 24Option Exercise18.90210,2803,974,292622,467Feb 26 03:05 PM
Dolsten MikaelPresident R&DFeb 24Option Exercise18.90210,2803,974,292577,902Feb 26 03:05 PM
HILL CHARLES HExecutive Vice PresidentFeb 24Option Exercise18.9078,8551,490,360149,135Feb 26 03:05 PM
JOHNSON RADY AExecutive Vice PresidentFeb 24Option Exercise18.9019,188362,65366,048Feb 26 03:05 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 24Option Exercise18.9034,171645,832149,482Feb 26 03:05 PM
BOURLA ALBERTGroup PresidentFeb 24Option Exercise18.9030,666579,587144,675Feb 26 03:03 PM
BOURLA ALBERTGroup PresidentDec 15Option Exercise26.2030,000786,000140,560Dec 16 06:46 PM
YOUNG JOHN DGroup PresidentDec 14Option Exercise26.2031,500825,300163,999Dec 16 06:55 PM
PFIZER INC10% OwnerOct 06Buy7.00714,2854,999,9952,253,509Oct 07 05:42 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerJul 30Sale35.6524,704880,646174,611Aug 03 07:24 AM